Dr. Priya Nandakumar brings scientific and clinical insight to The Catalyst Brief’s coverage of biomedical research and healthcare innovation. Her work bridges experimental findings, clinical data, and industry strategy, helping readers interpret what new evidence means beyond the lab or trial setting. At The Catalyst Brief, Priya emphasizes translational relevance and long-term implications for patients and pipelines.
160 articlesMostly Regulatory & Policy and Biopharmaceutical Industry
Healthcare InvestmentCandid Health's recent $120 million Series D financing signals a growing appetite among investors for AI-powered solutions aimed at streamlining healthcare administration. As the industry faces sustained financial pressures and regulatory complexity, automation of revenue cycle management is poised to play a transformative role.
Dr. Priya NandakumarJul 26, 2026
Regulatory & PolicyValue-based care (VBC) models have shifted the focus of healthcare from sheer volume to demonstrable outcomes, aiming for better efficiency and quality. Yet as rising and unpredictable costs continue to plague the industry, even well-designed VBC initiatives can falter. The delicate balance between lowering expenses and promoting holistic patient care remains one of healthcare’s greatest challenges in 2026.
Dr. Priya NandakumarJul 26, 2026
Regulatory & PolicyThe U.S. Food and Drug Administration’s advisory panel delivered a split decision on the future of peptide compounding by backing Epitalon and rejecting Emideltide. The proceedings exposed divergent perspectives on patient safety, regulatory standards, and the place of unapproved peptides in contemporary medicine.
Dr. Priya NandakumarJul 24, 2026
Biotech InnovationGSK's recently acquired molecule Jideytro (from Nuvalent) has received FDA approval for advanced non-small cell lung cancer driven by ROS1 genetic alterations. This development marks an important outcome of a $10.6 billion merger and positions GSK for a new presence in the competitive lung cancer drug market.
Dr. Priya NandakumarJul 23, 2026
Biotech InnovationTempus AI is making headlines with its $1.5 billion agreement to acquire Personalis, fusing two longstanding partners in the high-stakes arena of minimal residual disease (MRD) diagnostics. This move highlights the intensifying demand for non-invasive cancer detection tools and underscores broader shifts in how cancer patients will be diagnosed and monitored.
Dr. Priya NandakumarJul 21, 2026
Regulatory & PolicyAs the FDA embarks on a radical policy shift toward publishing drug rejections, the agency finds itself at the crossroads of transparency and legal ambiguity. Stakeholders warn of inadequate public debate and the risk of undermining regulatory norms as the debate intensifies.
Dr. Priya NandakumarJul 20, 2026
Medical TechnologyA growing number of healthcare entities have raised concerns over a perceived decline in trust surrounding interoperability, the seamless exchange and use of health data across multiple systems and organizations. This in-depth analysis explores what a so-called 'trust recession' could mean for the industry's digital maturity, and outlines what entities should be watching for as the next chapter in healthcare data unfolds.
Dr. Priya NandakumarJul 20, 2026
Biopharmaceutical IndustryBraveheart Bio, Attovia Therapeutics, and Vogenx are entering the public markets with focused plans to challenge some of the dominant players in the pharmaceutical industry. Their IPO ambitions highlight not just a buoyant capital environment, but also sharpened competitive aims in cardiometabolic and immunology drug development.
Dr. Priya NandakumarJul 16, 2026
Regulatory & PolicyClose to 200 healthcare providers, patient advocates, and industry organizations have endorsed the Clinical Trial Modernization Act. The bill intends to tackle financial and systemic gaps in access to clinical research, bringing new hope for increasing diversity and participation in essential trials.
Dr. Priya NandakumarJul 14, 2026
Medical TechnologyAs healthcare grows ever more data-driven, the focus of cybersecurity moves from patient privacy to the protection of scientific innovation. This article examines the new threats facing biotech R&D, the vital importance of intellectual property, and how the broadening risk landscape is reshaping organizational strategies across the medical sector.
Dr. Priya NandakumarJul 13, 2026
Regulatory & PolicyThe intersection of state budgetary decisions and caregiver livelihoods is reaching a critical point. With several states weighing deep wage cuts for family caregivers employed via Medicaid, ripple effects threaten not only economic security, but also care continuity for people with disabilities. Stakeholders grapple with how policy, economics, and compassion entwine in the U.S. caregiving landscape.
Dr. Priya NandakumarJul 13, 2026
Regulatory & PolicyWhile Medicaid has expanded coverage and services, the real test for plans is increasingly about meaningful connection with their highest-need members. Outreach effectiveness, not just service provision, is now emerging as the next major frontier in performance assessment for public health insurers.
Dr. Priya NandakumarJul 12, 2026